Terms: = Thyroid cancer AND TSC2, FLJ43106, 7249, ENSG00000103197, LAM, tuberin, TSC4
16 results:
1. Identification of a Novel tsc2 c.170G>A Missense Variant: A Case Report and Elaboration on the Yield of Targeted Options against Tuberous Sclerosis Complex Manifestations.
Papageorgiou G; Skouteris N; Valavanis C; Stanc GM; Souka E; Charalampakis N
Rev Recent Clin Trials; 2023; 18(4):304-312. PubMed ID: 37877150
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy and safety of anlotinib-based chemotherapy for locally advanced or metastatic anaplastic thyroid carcinoma.
Zheng X; Wang J; Ye T; Tang W; Pan X; Wang S; Liu J
Endocrine; 2023 Sep; 81(3):540-546. PubMed ID: 37219702
[TBL] [Abstract] [Full Text] [Related]
3. Rare manifestations and malignancies in tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increAse disease awareness (TOSCA).
Sauter M; Belousova E; Benedik MP; Carter T; Cottin V; Curatolo P; Dahlin M; D'Amato L; d'Augères GB; de Vries PJ; Ferreira JC; Feucht M; Fladrowski C; Hertzberg C; Jozwiak S; Lawson JA; Macaya A; Marques R; Nabbout R; O'Callaghan F; Qin J; Sander V; Shah S; Takahashi Y; Touraine R; Youroukos S; Zonnenberg B; Jansen A; Kingswood JC;
Orphanet J Rare Dis; 2021 Jul; 16(1):301. PubMed ID: 34229737
[TBL] [Abstract] [Full Text] [Related]
4. Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization.
Chu YH; Wirth LJ; Farahani AA; Nosé V; Faquin WC; Dias-Santagata D; Sadow PM
Mod Pathol; 2020 Dec; 33(12):2458-2472. PubMed ID: 32737449
[TBL] [Abstract] [Full Text] [Related]
5. The pleura and the endocrine system.
Sorino C; Negri S; Spanevello A; Feller-Kopman D
Eur J Intern Med; 2020 Feb; 72():34-37. PubMed ID: 31918926
[TBL] [Abstract] [Full Text] [Related]
6. Multifaceted roles of ATM in autophagy: From nonselective autophagy to selective autophagy.
Liang N; He Q; Liu X; Sun H
Cell Biochem Funct; 2019 Apr; 37(3):177-184. PubMed ID: 30847960
[TBL] [Abstract] [Full Text] [Related]
7. Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling.
Khan SA; Ci B; Xie Y; Gerber DE; Beg MS; Sherman SI; Cabanillas ME; Busaidy NL; Burtness BA; Heilmann AM; Bailey M; Ross JS; Sher DJ; Ali SM
Head Neck; 2019 Jun; 41(6):1928-1934. PubMed ID: 30758123
[TBL] [Abstract] [Full Text] [Related]
8. NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma.
Tiedje V; Ting S; Herold T; Synoracki S; Latteyer S; Moeller LC; Zwanziger D; Stuschke M; Fuehrer D; Schmid KW
Oncotarget; 2017 Jun; 8(26):42613-42620. PubMed ID: 28489587
[TBL] [Abstract] [Full Text] [Related]
9. mTOR activation is critical for betulin treatment in renal cell carcinoma cells.
Cheng W; Ji S; Zhang H; Han Z; Liu Q; Wang J; Ping H
Biochem Biophys Res Commun; 2017 Jan; 482(4):1030-1036. PubMed ID: 27908730
[TBL] [Abstract] [Full Text] [Related]
10. Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.
Lim SM; Park HS; Kim S; Kim S; Ali SM; Greenbowe JR; Yang IS; Kwon NJ; Lee JL; Ryu MH; Ahn JH; Lee J; Lee MG; Kim HS; Kim H; Kim HR; Moon YW; Chung HC; Kim JH; Kang YK; Cho BC
Oncotarget; 2016 Mar; 7(9):10547-56. PubMed ID: 26859683
[TBL] [Abstract] [Full Text] [Related]
11. Metformin inhibits thyroid cancer cell growth, migration, and EMT through the mTOR pathway.
Han B; Cui H; Kang L; Zhang X; Jin Z; Lu L; Fan Z
Tumour Biol; 2015 Aug; 36(8):6295-304. PubMed ID: 25854169
[TBL] [Abstract] [Full Text] [Related]
12. Response and acquired resistance to everolimus in anaplastic thyroid cancer.
Wagle N; Grabiner BC; Van Allen EM; Amin-Mansour A; Taylor-Weiner A; Rosenberg M; Gray N; Barletta JA; Guo Y; Swanson SJ; Ruan DT; Hanna GJ; Haddad RI; Getz G; Kwiatkowski DJ; Carter SL; Sabatini DM; Jänne PA; Garraway LA; Lorch JH
N Engl J Med; 2014 Oct; 371(15):1426-33. PubMed ID: 25295501
[TBL] [Abstract] [Full Text] [Related]
13. A novel tumor marker, Niban, is expressed in subsets of thyroid tumors and Hashimoto's thyroiditis.
Matsumoto F; Fujii H; Abe M; Kajino K; Kobayashi T; Matsumoto T; Ikeda K; Hino O
Hum Pathol; 2006 Dec; 37(12):1592-600. PubMed ID: 16949643
[TBL] [Abstract] [Full Text] [Related]
14. Hyperplasia of type II pneumocytes in pulmonary lymphangioleiomyomatosis.
Matsui K; K Riemenschneider W; Hilbert SL; Yu ZX; Takeda K; Travis WD; Moss J; Ferrans VJ
Arch Pathol Lab Med; 2000 Nov; 124(11):1642-8. PubMed ID: 11079017
[TBL] [Abstract] [Full Text] [Related]
15. The expression of hamartin, the product of the TSC1 gene, in normal human tissues and in TSC1- and tsc2-linked angiomyolipomas.
Plank TL; Logginidou H; Klein-Szanto A; Henske EP
Mod Pathol; 1999 May; 12(5):539-45. PubMed ID: 10349994
[TBL] [Abstract] [Full Text] [Related]
16. Extrathoracic angiomyolipomas in lymphangioleiomyomatosis.
Maziak DE; Kesten S; Rappaport DC; Maurer J
Eur Respir J; 1996 Mar; 9(3):402-5. PubMed ID: 8729995
[TBL] [Abstract] [Full Text] [Related]
